(Total Views: 727)
Posted On: 01/30/2023 3:26:58 PM
Post# of 148890
I recall the saying. "Idle minds are the devil's workshop." Well, my mind is idle, but I've been pondering some questions about some previous leronlimab activity.
What was the outcome of the Canadian approval for one patient to be treated for cancer?
Quote:
"Health Canada Authorizes Emergency Use of Leronlimab for Treatment of First Triple-Negative Breast Cancer Patient in Canada
Nov 16, 2021, 04:00 pm
VANCOUVER, Wash. --
CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that Health Canada authorized the emergency use of leronlimab for the treatment of a patient with metastatic triple-negative breast cancer (mTNBC).:
What was the result of the patients treated for Covid in the Philippines under the compassionate use authorization? Are they still purchasing vials of leronlimab?
What was the result of the (limited) trial for critical Covid patients in Brazil?
Has there been any reports of progress on the study being conducted at MD Anderson in Houston?
Has there been any reports of progress on the UK study of leronlimab in treating Alzheimer's?
As we approach the end of our 42nd week of arbitration with Amarex, are we nearing a decision on the verdict?
What is "LivImmune" and where did it go?
Wondering about the paper that was going to be published about the oral longer lasting HIV dosage.
Let's not forget to mention the "partial hold" on leronlimab by the FDA since mid 2022.
Just killing' time-no response needed or expected.
What was the outcome of the Canadian approval for one patient to be treated for cancer?
Quote:
"Health Canada Authorizes Emergency Use of Leronlimab for Treatment of First Triple-Negative Breast Cancer Patient in Canada
Nov 16, 2021, 04:00 pm
VANCOUVER, Wash. --
CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that Health Canada authorized the emergency use of leronlimab for the treatment of a patient with metastatic triple-negative breast cancer (mTNBC).:
What was the result of the patients treated for Covid in the Philippines under the compassionate use authorization? Are they still purchasing vials of leronlimab?
What was the result of the (limited) trial for critical Covid patients in Brazil?
Has there been any reports of progress on the study being conducted at MD Anderson in Houston?
Has there been any reports of progress on the UK study of leronlimab in treating Alzheimer's?
As we approach the end of our 42nd week of arbitration with Amarex, are we nearing a decision on the verdict?
What is "LivImmune" and where did it go?
Wondering about the paper that was going to be published about the oral longer lasting HIV dosage.
Let's not forget to mention the "partial hold" on leronlimab by the FDA since mid 2022.
Just killing' time-no response needed or expected.
(14)
(0)Scroll down for more posts ▼
